Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED)

v3.20.1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Beginning balance, shares at Dec. 31, 2018 256,123,515      
Beginning balance, value at Dec. 31, 2018 $ 256,123 $ 111,429,877 $ (113,168,000) $ (1,482,000)
Common stock issued on exercise of warrants and options, shares 1,962,153      
Common stock issued on exercise of warrants and options, value $ 1,962 170,038   172,000
Fair value of common stock issued on conversion of notes payable, shares 36,719,820      
Fair value of common stock issued on conversion of notes payable, value $ 36,720,000 1,799,280   1,836,000
Fair value of warrants and beneficial conversion feature of issued convertible notes   668,000   668,000
Fair value of options and warrants issued as compensation   99,000   99,000
Net loss     (2,282,000) (2,282,000)
Ending balance, shares at Mar. 31, 2019 294,805,488      
Ending balance, value at Mar. 31, 2019 $ 294,805 114,166,195 (115,450,000) (989,000)
Beginning balance, shares at Dec. 31, 2019 310,111,536      
Beginning balance, value at Dec. 31, 2019 $ 310,111 116,209,889 (118,789,000) (2,269,000)
Common stock issued on exercise of warrants and options, shares 1,215,000      
Common stock issued on exercise of warrants and options, value $ 1,215 59,785   61,000
Fair value of common stock issued on conversion of notes payable, shares 3,645,673      
Fair value of common stock issued on conversion of notes payable, value $ 3,646 215,354   219,000
Fair value of warrants and beneficial conversion feature of issued convertible notes   35,000   35,000
Fair value of options and warrants issued as compensation   121,000   121,000
Net loss     (766,000) (766,000)
Ending balance, shares at Mar. 31, 2020 314,972,209      
Ending balance, value at Mar. 31, 2020 $ 314,972 $ 116,641,028 $ (119,555,000) $ (2,599,000)